Nepafenac

證據等級: L5

預測適應症: 10 個

Nepafenac: From Ocular Inflammation (Established Use) to Eye Disease (Broad TxGNN Prediction)

One-Sentence Summary

Nepafenac is a topical ophthalmic NSAID with well-documented efficacy in preventing and treating inflammation and pain after cataract surgery, though it is not currently marketed in Norway. The TxGNN model's top prediction for this drug is the broad category Eye Disease, with over 40 clinical trials and 20 publications — largely reflecting its already-established ophthalmic anti-inflammatory use rather than a genuinely novel indication.

Quick Overview

Item	Content
Original Indication	Not documented in the regulatory record (no Norway licenses on file); extensively evidenced in clinical trial data as ocular inflammation and pain associated with cataract surgery
Predicted New Indication	Eye disease
TxGNN Prediction Score	99.85%
Evidence Level	L1
Norway Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the evidence pack. Based on the clinical trial and literature evidence collected, nepafenac is a topical ophthalmic NSAID prodrug that, after ocular penetration, is converted to its active metabolite amfenac, which inhibits cyclooxygenase (COX-1/COX-2) and thereby reduces prostaglandin-mediated inflammation in ocular tissue.

Its efficacy in preventing and treating inflammation and pain after cataract surgery is extensively documented — over 40 registered trials and multiple completed Phase 3 RCTs (some with enrollment exceeding 2,000 subjects) consistently support this use, and a 2025 systematic review/meta-analysis (PMID 39936354) confirms its benefit in reducing macular swelling and improving visual outcomes post-cataract surgery.

The TxGNN prediction of "eye disease" is therefore mechanistically unsurprising: it largely reflects the drug's already-known anti-inflammatory activity across ocular conditions (cataract surgery inflammation, diabetic macular edema, laser iridotomy inflammation) rather than identifying a distinct, unmet new indication. Preclinical data further suggest an anti-angiogenic effect on retinal vasculature (PMID 19897019, PMID 17259381), which could extend applicability to diabetic retinopathy-related conditions, but this remains largely at the mechanistic/preclinical level for indications beyond post-surgical inflammation.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01109173	Phase 3	Completed	2120	Safety and efficacy of nepafenac 0.3% for prevention/treatment of ocular inflammation and pain after cataract extraction
NCT01318499	Phase 2	Completed	1342	Nepafenac 0.3% vs 0.1% vs vehicle for post-cataract inflammation and pain
NCT01853072	Phase 3	Completed	881	Nepafenac 0.3% once-daily superior to vehicle in diabetic subjects post-cataract surgery
NCT01872611	Phase 3	Completed	819	Confirmatory Phase 3 replicate of NCT01853072 in diabetic post-cataract patients
NCT03025945	NA	Completed	662	Adjunctive nepafenac 0.3% vs placebo for pseudophakic cystoid macular edema prevention
NCT03499873	Phase 3	Completed	448	Bioequivalence of generic nepafenac 0.3% vs Ilevro for post-cataract pain/inflammation
NCT00333255	Phase 3	Completed	267	Nepafenac 0.1% vs Acular LS for treatment of ocular inflammation after cataract surgery
NCT01426854	Phase 3	Completed	260	Nepafenac 0.1% vs placebo for prevention/treatment of post-cataract inflammation and pain in Chinese subjects
NCT00405730	Phase 3	Completed	227	European study: nepafenac 0.1% vs ketorolac vs placebo for post-cataract inflammation/pain
NCT00939276	Phase 3	Terminated	175	Nepafenac for macular edema incidence/severity reduction in diabetic retinopathy post-cataract surgery

Literature Evidence

PMID	Year	Type	Journal	Key Findings
39936354	2025	Systematic Review & Meta-analysis	Eur J Ophthalmol	Nepafenac reduces foveal thickness and improves visual outcomes when added to steroid regimen post-cataract surgery
32672612	2020	RCT	Ophthalmology Glaucoma	Nepafenac 0.1% comparable to prednisolone acetate for controlling inflammation after laser peripheral iridotomy
24345529	2014	Phase 3 RCT	J Cataract Refract Surg	Once-daily nepafenac 0.3% effective for prevention/treatment of post-cataract inflammation and pain
24345317	2014	RCT	Am J Ophthalmol	Nepafenac 0.1% eye drops do not significantly raise intraocular pressure
22795976	2012	RCT	J Cataract Refract Surg	Prophylactic nepafenac and ketorolac both superior to placebo in preventing post-phacoemulsification macular edema
19040348	2008	RCT	J Ocul Pharmacol Ther	Dosing frequency comparison (QD/BID/TID) for nepafenac in post-cataract pain and inflammation
34120417	2021	Comparative Clinical Study	Korean J Ophthalmol	Nepafenac 0.1% vs prednisolone acetate 1% for inflammation control after micro-incisional cataract surgery
30284393	2018	Comparative Clinical Study	Acta Ophthalmol	Nepafenac vs preservative-free diclofenac for prevention of pseudophakic cystoid macular oedema
34210237	2022	Review	Clin Exp Optom	Review of nepafenac's role, penetration, and safety profile in cataract surgery
35025078	2022	Review	Drugs	Review of diagnostic and therapeutic agents (including NSAIDs) for non-infectious corneal injury

Norway Market Information

Nepafenac is currently not marketed in Norway (0 authorizations on file). No product license records are available in the evidence pack.

Safety Considerations

Please refer to the package insert for safety information. No detailed warnings, contraindications, or drug interaction data are currently available in the evidence pack (flagged as a Blocking data gap — TFDA/label warnings — pending retrieval and parsing from the official product insert).

Conclusion and Next Steps

Decision: Hold

Rationale: While clinical trial and literature evidence for nepafenac's anti-inflammatory ocular activity is strong (L1, multiple completed Phase 3 RCTs), the TxGNN-predicted indication ("eye disease") is non-specific and largely overlaps with the drug's already-established use rather than representing a novel repurposing opportunity. Combined with the absence of any Norway market presence and a blocking gap in safety/label data, a full go/no-go decision cannot yet be made.

To proceed, the following is needed:

TFDA/product insert warnings and contraindications (Blocking gap, DG001)
Confirmed mechanism of action documentation (DG002)
Clarification of the specific eye disease sub-indication targeted by the TxGNN prediction (the current label is too broad for regulatory or clinical decision-making)
Norway-specific regulatory pathway assessment, since the drug currently holds no local authorization
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.